{"Clinical Trial ID": "NCT00632489", "Intervention": ["INTERVENTION 1:", "LBH589 with capecitabine", "BAT, LBH589 with capecitabine", "LBH589: LBH589 will be evaluated twice a week at the following possible doses: 20 mg, 30 mg, 45 mg and 60 mg. Capecitabine will be combined with LBH589 and will vary in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 every 21 days. Treatment cycles will last 21 days. Once safety is established, 10 additional patients will be treated with BAT determined to assess safety.", "Capecitabine: Capecitabine is administered orally twice a day for 14 days over 21 days.", "INTERVENTION 2:", "LBH589 and Lapatinib", "LBH589 and Lapatinib", "LBH589: LBH589 will be evaluated twice a week at the following possible doses: 20 mg, 30 mg, 45 mg and 60 mg. Capecitabine will be combined with LBH589 and will vary in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 every 21 days. Treatment cycles will last 21 days. Once safety is established, 10 additional patients will be treated with BAT determined to assess safety.", "Lapatinib: Lapatinib, 1000 mg PO per day will be added to this combination."], "Eligibility": ["Incorporation criteria:", "Incurable, metastatic or locally unresectable malignancy, documented histologically, for which capecitabine is clinically appropriate.", "* Male or female patients aged 18 years.", "A maximum of 3 previous treatments in a metastatic context is allowed and may include other targeted agents, immunotherapy and chemotherapy.", "A disease measurable according to the criteria for assessing response in solid tumours (RECIST).", "Eastern Cooperative Oncology Group (ECOG PS) 0 or 1.", "The basic MUGA or ECHO must demonstrate that the LVEF is above the lower limits of institutional normal.", "Laboratory values as follows:", "ANC > 1500/\u03bcL", "Hgb > 9 g/dL", "Blisters > 100 000/uL", "Bilirubine < 1.5 mg/dL", "AST/SGOT < 2.5 x ULN or < 5.0 x ULN and ALT/SGPT in patients with hepatic metastases", "Creatinine < 1.5 mg/dL or creatinine clearance > 50 ml/min", "Albumin > 3 g/dL", "Potassium > lower limit of normal (LLN)", "Phosphorus > LLN", "Calcium > LLN", "- Magnesium > LLN - - - - - - - - - - - Magnesium > LLN - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -", "Women of childbearing potential should undergo a negative serum or urinary pregnancy test within 7 days of starting treatment and commit to start two acceptable methods of contraception, a highly effective method of contraception and an additional effective method at the same time before starting treatment.", "Life expectancy > 12 weeks.", "Available for treatment and follow-up.", "All patients should be able to understand the nature of the study and give informed written consent before entering the study.", "Other subset of breast cancer patients (Part 2 and Part 3) Inclusion Criteria:", "Incurable breast carcinoma, with locally recidivating or measurable metastatic disease.", "- ICH 3+ overexpression or FISH amplification documented by a local laboratory in primary or metastatic tumour tissue.", "A prior treatment with anthracycline, taxane, and trastuzumab or not for such treatment. The patient may have received these medicines in combination or in sequence for the treatment of locally advanced or metastatic disease and/or adjuvant treatment.", "- Exclusion criteria:", "Prior treatment with HDAC inhibitor or current treatment with valproic acid.", "Previous treatment with capecitabine.", "- Impairment of cardiac function, including any of the following:", "ECG screening with a QTc > 450 msec.", "\u2022 Long-term congenital QT syndrome.", "\u2022 History of prolonged ventricular tachycardia.", "Any history of ventricular fibrillation or twisting of spikes.", "Bradycardia defined as heart rate < 50 beats per minute. Patients with a heart pacemaker and heart rate > 50 beats per minute are eligible.", "\u2022 Myocardial infarction or unstable angina within 6 months of entry into the study.", "- Congestive heart failure (NY Heart Association class III or IV).", "- Right beam branch block and left front hemibloc (bifascicular block).", "Atrial fibrillation or fluttering.", "During treatment with antiarrhythmics or other medicinal products associated with QTc prolongation.", "Uncorrected hypokalaemia or hypomagnesaemia.", "Uncontrolled hypertension (systolic arterial pressure [BP] 180 or diastolic BP > 100 mm Hg) or uncontrolled cardiac arrhythmias.", "Active CNS disease, including meningation metastases.", "\u2022 A known diagnosis of human immunodeficiency virus (HIV) infection.", "Unsolved Diarrhoea > CATAE grade 1.", "- Concomitant requirement for medicinal products classified as CYP3A4 inducers or inhibitors.", "* Patients with a history of allergic reactions attributed to compounds of chemical or biological composition similar to lapatinib.", "Patients with known hypersensitivity to 5-fluorouracil chemotherapy, experimental pharmacotherapy, major surgery < 4 weeks prior to the start of the study or to patients who have not recovered from the side effects of previous treatment.", "The patient is < 5 years free from another primary malignancy, unless the other primary malignancy is currently not clinically significant or requires active intervention, or if another primary malignancy is basal cell skin cancer or cervical carcinoma in situ. The existence of another malignant disease is not permitted.", "The concomitant use of any anticancer therapy or radiotherapy.", "Breastfeeding or breastfeeding or reproduction of the female does not use two effective methods of birth control.", "* Male patients whose sexual partners are women of childbearing age who do not use effective birth control.", "* Patients with gastrointestinal disease (GI), cause of inability to take oral medication, malabsorption syndrome, need for intravenous feeding (IV), previous surgical procedures affecting absorption, uncontrolled IG inflammatory disease (e.g. Crohn's disease, ulcerative colitis).", "Other co-occurring serious, uncontrolled or intercurrent infections, including, but not limited to, permanent or active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia or psychiatric/social situations that would limit compliance with the requirements of the study.", "Patients taking all drugs listed in \"Prohibited Medicines\" for capecitabine and lapatinib.", "Patients with uncontrolled coagulopathy (PT and/or PTT > 1.2 x ULN; the patient should also receive a stable dose of anticoagulant for a defined medical indication).", "In patients with known hypothyroidism who are stable during thyroid replacement are eligible.", "Other subset of breast cancer patients (Part 2 and Part 3) Exclusion Criteria:", "1. Prior treatment with lapatinib"], "Results": ["Performance measures:", "To determine maximum tolerated doses (LDT) and limit doses of LBH589 in combination with capecitabine when administered to patients with refractory and advanced types of 5-fluorouracil-sensitive tumours", "BAT for Capecitabine, BID", "Time limit: 18 months", "Results 1:", "Title of the arm/group: LBH589 with capecitabine", "Description of the arm/group: BAT, LBH589 with capecitabine", "LBH589: LBH589 will be evaluated twice a week at the following possible doses: 20 mg, 30 mg, 45 mg and 60 mg. Capecitabine will be combined with LBH589 and will vary in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 every 21 days. Treatment cycles will last 21 days. Once safety is established, 10 additional patients will be treated with BAT determined to assess safety.", "Capecitabine: Capecitabine is administered orally twice a day for 14 days over 21 days.", "Total number of participants analysed: 15", "Type of measurement: Number", "Unit of measurement: mg/m2 100", "Results 2:", "Title of arm/group: LBH589 and Lapatinib", "Description of the arm/group: LBH589 and Lapatinib", "LBH589: LBH589 will be evaluated twice a week at the following possible doses: 20 mg, 30 mg, 45 mg and 60 mg. Capecitabine will be combined with LBH589 and will vary in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 every 21 days. Treatment cycles will last 21 days. Once safety is established, 10 additional patients will be treated with BAT determined to assess safety.", "Lapatinib: Lapatinib, 1000 mg PO per day will be added to this combination.", "Total number of participants analysed: 0", "Type of measurement: Number", "Unit of measurement: mg/m2"], "Adverse Events": ["Undesirable Events 1:", "Total: 6/15 (40.00 per cent)", "Constipation 1/15 (6.67 per cent)", "General disorders and administration site conditions - Other, disease progression 2/15 (13.33%)", "General disorders and administration site conditions - Other, growth failure 0/15 (0.00 %)", "\u2022 Infections and infestations - Other infections not specified 1/15 (6.67%)", "Decrease in platelet count 1/15 (6.67 per cent)", "Dehydration 0/15 (0.00 per cent)", "Adverse Events 2:", "Total: 3/5 (60.00 per cent)", "Constipation 0/5 (0.00 %)", "General disorders and administration site conditions - Other, disease progression 1/5 (20.00%)", "General disorders and administration site conditions - Other, growth failure 1/5 (20.00%)", "Infections and Infestations - Other Unspecified Infections 0/5 (0.00 %)", "Decrease in platelet count 0/5 (0.00 %)", "Dehydration 1/5 (20.00%)", "- Dysarthrie 0/5 (0.00 %)"]}